Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/4/2024 | Outperform | William Blair | |
| 12/19/2023 | $13.00 → $4.00 | Equal-Weight → Underweight | Morgan Stanley |
| 10/18/2023 | $23.00 | Mkt Outperform | JMP Securities |
| 3/31/2023 | $15.00 | Buy | Mizuho |
| 9/16/2022 | $19.00 | Outperform | Wedbush |
| 8/29/2022 | $24.00 | Buy | H.C. Wainwright |
| 2/1/2022 | $17.00 | Equal-Weight | Morgan Stanley |
| 2/1/2022 | $23.00 | Buy | Guggenheim |
4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
- Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for
VGL101 demonstrated favorable safety, tolerability and PK profiles in single ascending dose and multiple ascending dose cohortsVGL101 achieved dose dependent, robust and durable decreases in CSF sTREM2 demonstrating proof of target engagement further validating its mechanism of action On track to initiate Phase 2 trial with a 20 mg/kg dose of VGL101 in ALSP patients this quarterCompany to host conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced interim topline r
- Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for
– On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer's disease in Q3 2025 – WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ending March 31, 2025, and provided updates on its recent progress. "During the quarter, we continued to make meaningful progress across our two TREM2 programs, VG-3927 and iluzanebart," said Ivana Ma
- Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 - - First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer's disease (AD) - WATERTOWN, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented data highlighting its oral small molecule program, including its lead clinical candidate VG-3927, in two oral presentations at the AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Dis
4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
4 - Vigil Neuroscience, Inc. (0001827087) (Issuer)
SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)
SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)
SC 13D/A - Vigil Neuroscience, Inc. (0001827087) (Subject)
DEFA14A - Vigil Neuroscience, Inc. (0001827087) (Filer)
DEFA14A - Vigil Neuroscience, Inc. (0001827087) (Filer)
DEFA14A - Vigil Neuroscience, Inc. (0001827087) (Filer)
William Blair initiated coverage of Vigil Neuroscience with a rating of Outperform
Morgan Stanley downgraded Vigil Neuroscience from Equal-Weight to Underweight and set a new price target of $4.00 from $13.00 previously
JMP Securities initiated coverage of Vigil Neuroscience with a rating of Mkt Outperform and set a new price target of $23.00
Augustine Therapeutics appoints Gerhard Koenigas Chief Executive Officer as Company Prepares to Enter the Clinic Industry veteran Gerhard Koenig, PhD, current Executive Chairman, appointed as CEOBest-in-class highly selective HDAC6 inhibitor pioneer for disease-modifying treatment of neuromuscular, neurodegenerative and cardiometabolic diseases poised to enter the clinic LEUVEN, Belgium – February 13, 2025 – Augustine Therapeutics ("Augustine" or "the Company"), a preclinical-stage biotechnology company focused on innovative therapies for neuromuscular, neurodegenerative and cardiometabolic diseases through the inhibition of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, today announc
Proceeds will advance lead candidate AGT100216, a peripherally restricted and selective HDAC6 inhibitor, into a first-in-human clinical Phase 1/2 study Gerhard Koenig appointed as executive chairman of Augustine's Board of Directors Augustine Therapeutics, a pioneering biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, today announced that it has raised EUR 17 million (USD 18.5 million) in the first closing of its Series A round. The financing was led by Asabys Partners, with participation from Eli Lilly and Company, and the US-based Charcot-Marie-Tooth Research Foundation. Current investors AdBio partners, V-Bio Ventures, PMV, VIB and Gem
– Enrollment completed for Phase 2 trial evaluating iluzanebart in ALSP; Next data readout planned for Q3 2024 – – Phase 1 healthy volunteer trial evaluating VG-3927 for Alzheimer's disease ongoing; Interim data analysis on track for mid-2024 – WATERTOWN, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent progress. "During the quarter, we continued to progress iluzanebart, our monoclonal antibody, and VG-3927, our or